{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:52:09Z","timestamp":1773478329242,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00108-025-02026-9","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:02:07Z","timestamp":1767783727000},"page":"166-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neue antimikrobielle Substanzen gegen zunehmende Resistenzen","New antimicrobial substances to combat increasing resistance"],"prefix":"10.1007","volume":"67","author":[{"given":"Jasmin","family":"Tischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Trawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2026_CR1","unstructured":"O\u2019Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Resistance: Final Report and Recommendations. https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf"},{"issue":"10442","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/S0140-6736(24)01076-6","volume":"403","author":"The Lancet","year":"2024","unstructured":"The Lancet (2024) Antimicrobial resistance: an agenda for all. Lancet 403(10442):2349","journal-title":"Lancet"},{"key":"2026_CR3","unstructured":"WHO (2024) Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376776\/9789240093461-eng.pdf?sequence=1"},{"issue":"10459","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a\u00a0systematic analysis with forecasts to 2050. Lancet 404(10459):1199\u20131226","journal-title":"Lancet"},{"issue":"6","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1473-3099(22)00796-4","volume":"23","author":"J Patel","year":"2023","unstructured":"Patel\u00a0J, Harant\u00a0A, Fernandes\u00a0G, Mwamelo\u00a0AJ, Hein\u00a0W, Dekker\u00a0D et\u00a0al (2023) Measuring the global response to antimicrobial resistance, 2020\u201321: a\u00a0systematic governance analysis of 114 countries. Lancet Infect Dis 23(6):706\u2013718","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","volume":"64","author":"R Ackley","year":"2020","unstructured":"Ackley\u00a0R, Roshdy\u00a0D, Meredith\u00a0J, Minor\u00a0S, Anderson\u00a0WE, Capraro\u00a0GA et\u00a0al (2020) Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother 64(5):e2313\u201319","journal-title":"Antimicrob Agents Chemother"},{"issue":"10325","key":"2026_CR7","first-page":"62955","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a\u00a0systematic analysis. Lancet 399(10325):62955","journal-title":"Lancet"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"SS Jean","year":"2022","unstructured":"Jean\u00a0SS, Harnod\u00a0D, Hsueh\u00a0PR (2022) Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. Front Cell Infect Microbiol 12:823684","journal-title":"Front Cell Infect Microbiol"},{"key":"2026_CR9","unstructured":"ECDC (2024) Antimicrobial Resistance in the EU\/EEA (EARS-Net) Annual Epidemiological Report for 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2023"},{"key":"2026_CR10","unstructured":"Pfennigwerth N, M\u00f6ller S, Eisfeld J et\u00a0al (2025) Bericht des Nationalen referenzzentrums f\u00fcr gramnegative Krankenhauserreger f\u00fcr das Jahr 2024. https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2025\/20-21_25.pdf?__blob=publicationFile&v=4"},{"issue":"9","key":"2026_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","volume":"25","author":"H Sati","year":"2025","unstructured":"Sati\u00a0H, Carrara\u00a0E, Savoldi\u00a0A, Hansen\u00a0P, Garlasco\u00a0J, Campagnaro\u00a0E et\u00a0al (2025) The WHO Bacterial Priority Pathogens List 2024: a\u00a0prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis 25(9):1033\u20131043","journal-title":"Lancet Infect Dis"},{"key":"2026_CR12","unstructured":"G\u2011BA (2021) Reserveantibiotika \u2013 keine regul\u00e4re Nutzenbewertung. https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/reserveantibiotika\/"},{"key":"2026_CR13","unstructured":"G\u2011BA Bewertungsverfahren. https:\/\/www.g-ba.de\/bewertungsverfahren\/"},{"key":"2026_CR14","unstructured":"G\u2011BA Beschl\u00fcsse Reserveantibiotika. https:\/\/www.g-ba.de\/beschluesse\/zum-thema\/223\/"},{"key":"2026_CR15","unstructured":"Action Fund AMR (2025) Enabling Breakthroughs in Antimicrobials: 2 TO 4 NOVEL ANTIBIOTICS BY 2030. https:\/\/www.amractionfund.com"},{"issue":"7","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"e0231820","DOI":"10.1128\/AAC.02318-20","volume":"65","author":"BD Lizza","year":"2021","unstructured":"Lizza\u00a0BD, Betthauser\u00a0KD, Ritchie\u00a0DJ, Micek\u00a0ST, Kollef\u00a0MH (2021) New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrob Agents Chemother 65(7):e231820","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026_CR17","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav\u00a0D, Giske\u00a0CG, Gr\u0101matniece\u00a0A, Abodakpi\u00a0H, Tam\u00a0VH, Leibovici\u00a0L (2020) New \u03b2\u2011Lactam-\u03b2-Lactamase Inhibitor Combinations. Clin Microbiol Rev 34(1):e115\u201320","journal-title":"Clin Microbiol Rev"},{"issue":"10474","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic\u00a0N, Uhlemann\u00a0AC, Peleg\u00a0AY (2025) Multidrug-resistant Gram-negative bacterial infections. Lancet 405(10474):257\u2013272","journal-title":"Lancet"},{"key":"2026_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma\u00a0PD, Heil\u00a0EL, Justo\u00a0JA, Mathers\u00a0AJ, Satlin\u00a0MJ, Bonomo\u00a0RA (2024) Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciae403 (Aug 7: ciae403)","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026_CR20","doi-asserted-by":"publisher","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","volume":"7","author":"GL Daikos","year":"2025","unstructured":"Daikos\u00a0GL, Cisneros\u00a0JM, Carmeli\u00a0Y, Wang\u00a0M, Leong\u00a0CL, Pontikis\u00a0K et\u00a0al (2025) Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: a\u00a0Phase\u00a03 randomized trial (ASSEMBLE). JAC Antimicrob Resist 7(4):dlaf131","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"2026_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2025","unstructured":"Carmeli\u00a0Y, Cisneros\u00a0JM, Paul\u00a0M, Daikos\u00a0GL, Wang\u00a0M, Torre-Cisneros\u00a0J et\u00a0al (2025) Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a\u00a0descriptive, multinational, open-label, phase\u00a03, randomised trial. Lancet Infect Dis 25(2):218\u2013230","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2026_CR22","doi-asserted-by":"publisher","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","volume":"65","author":"EK McCreary","year":"2021","unstructured":"McCreary\u00a0EK, Heil\u00a0EL, Tamma\u00a0PD (2021) New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrob Agents Chemother 65(8):e217120","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","volume":"40","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy\u00a0S, Abdul-Mutakabbir\u00a0JC, Kebriaei\u00a0R, Jorgensen\u00a0SCJ, Rybak\u00a0MJ (2020) Evaluation of Eravacycline: A\u00a0Novel Fluorocycline. Pharmacotherapy 40(3):221\u2013238","journal-title":"Pharmacotherapy"},{"issue":"13","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","volume":"328","author":"KS Kaye","year":"2022","unstructured":"Kaye\u00a0KS, Belley\u00a0A, Barth\u00a0P, Lahlou\u00a0O, Knechtle\u00a0P, Motta\u00a0P et\u00a0al (2022) Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A\u00a0Randomized Clinical Trial. JAMA 328(13):1304\u20131314","journal-title":"JAMA"},{"issue":"7","key":"2026_CR25","doi-asserted-by":"publisher","first-page":"e00514","DOI":"10.1128\/AAC.00514-19","volume":"63","author":"I Morrissey","year":"2019","unstructured":"Morrissey\u00a0I, Magnet\u00a0S, Hawser\u00a0S, Shapiro\u00a0S, Knechtle\u00a0P (2019) In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015. Antimicrob Agents Chemother 63(7):e514\u201319","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2026_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/antibiotics14060587","volume":"14","author":"P Leroux","year":"2025","unstructured":"Leroux\u00a0P, Bornet\u00a0C, Bolla\u00a0JM, Cohen\u00a0A (2025) Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New \u03b2\u2011Lactamase Inhibitors and Antibiotics. Antibiot 14(6):587","journal-title":"Antibiot"},{"issue":"3","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"dlaf096","DOI":"10.1093\/jacamr\/dlaf096","volume":"7","author":"A Alarcia-Lacalle","year":"2025","unstructured":"Alarcia-Lacalle\u00a0A, Canut-Blasco\u00a0A, Solin\u00eds\u00a0M\u00c1, Isla\u00a0A, Rodr\u00edguez-Gasc\u00f3n\u00a0A (2025) Clinical efficacy, safety and pharmacokinetics of novel \u03b2\u2011lactam\/\u03b2-lactamase inhibitor combinations: a\u00a0systematic review. JAC Antimicrob Resist 7(3):dlaf96","journal-title":"JAC Antimicrob Resist"},{"key":"2026_CR28","unstructured":"Pew Charitable Trusts (2021) Tracking the Global Pipeline of Antibiotics in Development. https:\/\/www.pew.org\/en\/research-and-analysis\/issue-briefs\/2021\/03\/tracking-the-global-pipeline-of-antibiotics-in-development (March 2021)"},{"issue":"5","key":"2026_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/antibiotics14050528","volume":"14","author":"I Karaiskos","year":"2025","unstructured":"Karaiskos\u00a0I, Galani\u00a0I, Daikos\u00a0GL, Giamarellou\u00a0H (2025) Breaking Through Resistance: A\u00a0Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs. Antibiot 14(5):528","journal-title":"Antibiot"},{"issue":"4","key":"2026_CR30","first-page":"463","volume":"15","author":"L Principe","year":"2022","unstructured":"Principe\u00a0L, Lupia\u00a0T, Andriani\u00a0L, Campanile\u00a0F, Carcione\u00a0D, Corcione\u00a0S et\u00a0al (2022) Microbiological, Clinical, and PK\/PD Features of the New Anti-Gram-Negative Antibiotics: \u03b2\u2011Lactam\/\u03b2-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. Pharm 15(4):463","journal-title":"Pharm"},{"issue":"3","key":"2026_CR31","doi-asserted-by":"publisher","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","volume":"64","author":"JC Hamrick","year":"2020","unstructured":"Hamrick\u00a0JC, Docquier\u00a0JD, Uehara\u00a0T, Myers\u00a0CL, Six\u00a0DA, Chatwin\u00a0CL et\u00a0al (2020) VNRX-5133 (Taniborbactam), a\u00a0Broad-Spectrum Inhibitor of Serine- and Metallo-\u03b2-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64(3):e1963\u201319","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jac\/dkaa391","volume":"76","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq\u00a0S, Vickers\u00a0A, Doumith\u00a0M, Ellington\u00a0MJ, Woodford\u00a0N, Livermore\u00a0DM (2021) Activity of \u03b2\u2011lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J\u00a0Antimicrob Chemother 76(1):160\u2013170","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2026_CR33","doi-asserted-by":"publisher","first-page":"e0128122","DOI":"10.1128\/aac.01281-22","volume":"67","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky\u00a0JA, Hackel\u00a0MA, Wise\u00a0MG, Six\u00a0DA, Uehara\u00a0T, Daigle\u00a0DM et\u00a0al (2023) In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother 67(1):e128122","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2026_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","volume":"390","author":"FM Wagenlehner","year":"2024","unstructured":"Wagenlehner\u00a0FM, Gasink\u00a0LB, McGovern\u00a0PC, Moeck\u00a0G, McLeroth\u00a0P, Dorr\u00a0M et\u00a0al (2024) Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N\u00a0Engl J Med 390(7):611\u2013622","journal-title":"N Engl J Med"},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"697180","DOI":"10.3389\/fmicb.2021.697180","volume":"12","author":"O Lomovskaya","year":"2021","unstructured":"Lomovskaya\u00a0O, Tsivkovski\u00a0R, Sun\u00a0D, Reddy\u00a0R, Totrov\u00a0M, Hecker\u00a0S et\u00a0al (2021) QPX7728, An Ultra-Broad-Spectrum B\u2011Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Front Microbiol 12:697180","journal-title":"Front Microbiol"},{"issue":"1","key":"2026_CR36","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1128\/AAC.02184-15","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore\u00a0DM, Warner\u00a0M, Mushtaq\u00a0S, Woodford\u00a0N (2016) Interactions of OP0595, a\u00a0Novel Triple-Action Diazabicyclooctane, with \u03b2\u2011Lactams against OP0595-Resistant Enterobacteriaceae Mutants. Antimicrob Agents Chemother 60(1):554\u2013560","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2026_CR37","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","volume":"76","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq\u00a0S, Garello\u00a0P, Vickers\u00a0A, Woodford\u00a0N, Livermore\u00a0DM (2021) Activity of cefepime\/zidebactam (WCK 5222) against \u201aproblem\u2018 antibiotic-resistant Gram-negative bacteria sent to a\u00a0national reference laboratory. J\u00a0Antimicrob Chemother 76(6):1511\u20131522","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2026_CR38","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye\u00a0KS, Shorr\u00a0AF, Wunderink\u00a0RG, Du\u00a0B, Poirier\u00a0GE, Rana\u00a0K et\u00a0al (2023) Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a\u00a0multicentre, randomised, active-controlled, phase\u00a03, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 23(9):1072\u20131084","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2026_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Cloutier\u00a0DJ, Komirenko\u00a0AS, Cebrik\u00a0DS, Krause\u00a0KM, Keepers\u00a0TR et\u00a0al (2019) Once-Daily Plazomicin for Complicated Urinary Tract Infections. N\u00a0Engl J Med 380(8):729\u2013740","journal-title":"N Engl J Med"},{"issue":"3","key":"2026_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40121-019-0251-4","volume":"28","author":"JL Kuti","year":"2019","unstructured":"Kuti\u00a0JL, Kim\u00a0A, Cloutier\u00a0DJ, Nicolau\u00a0DP (2019) Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired\/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). Infect Dis Ther 28(3):383\u2013396","journal-title":"Infect Dis Ther"},{"issue":"10428","key":"2026_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","volume":"403","author":"F Wagenlehner","year":"2024","unstructured":"Wagenlehner\u00a0F, Perry\u00a0CR, Hooton\u00a0TM, Scangarella-Oman\u00a0NE, Millns\u00a0H, Powell\u00a0M et\u00a0al (2024) Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE\u20112 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase\u00a03, non-inferiority trials. Lancet 403(10428):741\u2013755","journal-title":"Lancet"},{"key":"2026_CR42","unstructured":"Dall C (2022) Trials for novel UTI antibiotic stopped early because of success. https:\/\/www.cidrap.umn.edu\/trials-novel-uti-antibiotic-stopped-early-because-success"},{"key":"2026_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-025-01970-w","author":"WV Kern","year":"2025","unstructured":"Kern\u00a0WV, Gatermann\u00a0SG (2025) Betalaktame und Betalaktamase-Inhibitoren \u2013 aktuelle Entwicklungen. Inn Med. https:\/\/doi.org\/10.1007\/s00108-025-01970-w (Online im Druck)","journal-title":"Inn Med"},{"issue":"14","key":"2026_CR44","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg\u00a0PB, Muir\u00a0L, Critchley\u00a0IA, Walpole\u00a0S, Kwak\u00a0H, Phelan\u00a0A\u2011M et\u00a0al (2022) Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N\u00a0Engl J Med 386(14):1327\u20131338","journal-title":"N Engl J Med"},{"issue":"3","key":"2026_CR45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s40121-021-00491-x","volume":"10","author":"L Puzniak","year":"2021","unstructured":"Puzniak\u00a0L, Dillon\u00a0R, Palmer\u00a0T, Collings\u00a0H, Enstone\u00a0A (2021) Systematic Literature Review of Real-world Evidence of Ceftolozane\/Tazobactam for the Treatment of Respiratory Infections. Infect Dis Ther 10(3):1227\u20131252","journal-title":"Infect Dis Ther"},{"issue":"5","key":"2026_CR46","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","volume":"25","author":"RK Shields","year":"2025","unstructured":"Shields\u00a0RK, Abbo\u00a0LM, Ackley\u00a0R, Aitken\u00a0SL, Albrecht\u00a0B, Babiker\u00a0A et\u00a0al (2025) Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a\u00a0multicentre, retrospective, observational study. Lancet Infect Dis 25(5):574\u2013584","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2026_CR47","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","volume":"75","author":"L Caro","year":"2020","unstructured":"Caro\u00a0L, Nicolau\u00a0DP, de Waele\u00a0JJ, Kuti\u00a0JL, Larson\u00a0KB, Gadzicki\u00a0E et\u00a0al (2020) Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3\u202fg of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia. J\u00a0Antimicrob Chemother 75(6):1546\u20131553","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2026_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antibiotics14010029","volume":"14","author":"MD Zilberberg","year":"2025","unstructured":"Zilberberg\u00a0MD, Nathanson\u00a0BH, Redell\u00a0MA, Sulham\u00a0K, Shorr\u00a0AF (2025) Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019\u20132021. Antibiot 14(1):29","journal-title":"Antibiot"},{"issue":"9","key":"2026_CR49","first-page":"1173","volume":"41","author":"O Lima","year":"2022","unstructured":"Lima\u00a0O, Sousa\u00a0A, Longueira-Su\u00e1rez\u00a0R, Filgueira\u00a0A, Taboada-Mart\u00ednez\u00a0C, Portela-Pino\u00a0C et\u00a0al (2022) Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 41(9):1173\u20131182","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2026_CR50","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad725","volume":"78","author":"M Falcone","year":"2024","unstructured":"Falcone\u00a0M, Giordano\u00a0C, Leonildi\u00a0A, Galfo\u00a0V, Lepore\u00a0A, Suardi\u00a0LR et\u00a0al (2024) Clinical Features and Outcomes of Infections Caused by Metallo-\u03b2-Lactamase-Producing Enterobacterales: A\u00a03-Year Prospective Study From an Endemic Area. Clin Infect Dis 78(5):1111\u20131119","journal-title":"Clin Infect Dis"},{"key":"2026_CR51","first-page":"101175","volume":"49","author":"IA Huespe","year":"2025","unstructured":"Huespe\u00a0IA, Huaier Arriazu\u00a0EF, Sanchez\u00a0M, Stanek\u00a0V, Poll\u00e1n\u00a0JA, Bauque\u00a0S et\u00a0al (2025) Mortality of metallo-\u03b2-lactamase-producing Enterobacterales bacteremias with combined ceftazidime-avibactam plus aztreonam vs. other active antibiotics: a\u00a0multicenter target trial emulation. Lancet Reg Health Am 49:101175","journal-title":"Lancet Reg Health Am"},{"issue":"8","key":"2026_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41579-025-01169-8","volume":"23","author":"U Theuretzbacher","year":"2025","unstructured":"Theuretzbacher\u00a0U (2025) The global resistance problem and the clinical antibacterial pipeline. Nat Rev Microbiol 23(8):491\u2013508","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"2026_CR53","doi-asserted-by":"publisher","first-page":"e00250","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"F Wittke","year":"2020","unstructured":"Wittke\u00a0F, Vincent\u00a0C, Chen\u00a0J, Heller\u00a0B, Kabler\u00a0H, Overcash\u00a0JS et\u00a0al (2020) Afabicin, a\u00a0First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin\/Linezolid. Antimicrob Agents Chemother 64(10):e250\u201320","journal-title":"Antimicrob Agents Chemother"},{"key":"2026_CR54","doi-asserted-by":"publisher","first-page":"114490","DOI":"10.1016\/j.ejmech.2022.114490","volume":"238","author":"N Sza\u0142aj","year":"2022","unstructured":"Sza\u0142aj\u00a0N, Benediktsdottir\u00a0A, Rusin\u00a0D, Karl\u00e9n\u00a0A, Mowbray\u00a0SL, Wi\u0119ckowska\u00a0A (2022) Bacterial type\u00a0I signal peptidase inhibitors\u2014Optimized hits from nature. Eur J Med Chem 238:114490","journal-title":"Eur J Med Chem"},{"issue":"23","key":"2026_CR55","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.cell.2021.10.010","volume":"184","author":"JR Buzzo","year":"2021","unstructured":"Buzzo\u00a0JR, Devaraj\u00a0A, Gloag\u00a0ES, Jurcisek\u00a0JA, Robledo-Avila\u00a0F, Kesler\u00a0T et\u00a0al (2021) Z\u2011form extracellular DNA is a\u00a0structural component of the bacterial biofilm matrix. Cell 184(23):5740\u20135758.e17","journal-title":"Cell"},{"issue":"1","key":"2026_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/antibiotics11010104","volume":"11","author":"JV Rogers","year":"2022","unstructured":"Rogers\u00a0JV, Hall\u00a0VL, McOsker\u00a0CC (2022) Crumbling the Castle: Targeting DNABII Proteins for Collapsing Bacterial Biofilms as a\u00a0Therapeutic Approach to Treat Disease and Combat Antimicrobial Resistance. Antibiot 11(1):104\u20132022","journal-title":"Antibiot"},{"key":"2026_CR57","doi-asserted-by":"publisher","first-page":"126719","DOI":"10.1016\/j.micres.2021.126719","volume":"246","author":"G Horna","year":"2021","unstructured":"Horna\u00a0G, Ruiz\u00a0J (2021) Type\u00a03 secretion system of Pseudomonas aeruginosa. Microbiol Res 246:126719","journal-title":"Microbiol Res"},{"issue":"7","key":"2026_CR58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/antibiotics9070397","volume":"9","author":"M Sarshar","year":"2020","unstructured":"Sarshar\u00a0M, Behzadi\u00a0P, Ambrosi\u00a0C, Zagaglia\u00a0C, Palamara\u00a0AT, Scribano\u00a0D (2020) FimH and Anti-Adhesive Therapeutics: A\u00a0Disarming Strategy Against Uropathogens. Antibiot 9(7):397","journal-title":"Antibiot"},{"issue":"1","key":"2026_CR59","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1038\/s41598-021-86155-9","volume":"11","author":"S Mandel","year":"2021","unstructured":"Mandel\u00a0S, Michaeli\u00a0J, Nur\u00a0N, Erbetti\u00a0I, Zazoun\u00a0J, Ferrari\u00a0L et\u00a0al (2021) OMN6 a\u00a0novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria. Sci Rep 11(1):6603","journal-title":"Sci Rep"},{"key":"2026_CR60","doi-asserted-by":"publisher","first-page":"175628482412530","DOI":"10.1177\/17562848241253089","volume":"17","author":"HL DuPont","year":"2024","unstructured":"DuPont\u00a0HL, DuPont\u00a0AW, Tillotson\u00a0GS (2024) Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therap Adv Gastroenterol 17:17562848241253089","journal-title":"Therap Adv Gastroenterol"},{"issue":"15","key":"2026_CR61","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna\u00a0S, Assi\u00a0M, Lee\u00a0C, Yoho\u00a0D, Louie\u00a0T, Knapple\u00a0W et\u00a0al (2022) Efficacy and Safety of RBX2660 in PUNCH CD3, a\u00a0Phase\u00a0III, Randomized, Double-Blind, Placebo-Controlled Trial with a\u00a0Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs 82(15):1527\u20131538","journal-title":"Drugs"},{"issue":"2","key":"2026_CR62","doi-asserted-by":"publisher","first-page":"e0051723","DOI":"10.1128\/spectrum.00517-23","volume":"11","author":"SP Sambol","year":"2023","unstructured":"Sambol\u00a0SP, Skinner\u00a0AM, Serna-Perez\u00a0F, Owen\u00a0B, Gerding\u00a0DN, Johnson\u00a0S (2023) Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with either Fidaxomicin or Vancomycin. Microbiol Spectr 11(2):e51723","journal-title":"Microbiol Spectr"},{"issue":"10","key":"2026_CR63","doi-asserted-by":"publisher","first-page":"113281","DOI":"10.1016\/j.celrep.2023.113281","volume":"42","author":"AE Campbell","year":"2023","unstructured":"Campbell\u00a0AE, McCready-Vangi\u00a0AR, Uberoi\u00a0A, Murga-Garrido\u00a0SM, Lovins\u00a0VM, White\u00a0EK et\u00a0al (2023) Variable staphyloxanthin production by Staphylococcus aureus drives strain-dependent effects on diabetic wound-healing outcomes. Cell Rep 42(10):113281","journal-title":"Cell Rep"},{"key":"2026_CR64","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2147\/IDR.S193649","volume":"12","author":"L Xue","year":"2019","unstructured":"Xue\u00a0L, Chen\u00a0YY, Yan\u00a0Z, Lu\u00a0W, Wan\u00a0D, Zhu\u00a0H (2019) Staphyloxanthin: a\u00a0potential target for antivirulence therapy. Infect Drug Resist 12:2151\u20132160","journal-title":"Infect Drug Resist"},{"issue":"1","key":"2026_CR65","doi-asserted-by":"publisher","first-page":"e01395","DOI":"10.1128\/AAC.01395-19","volume":"64","author":"BK Lomeli","year":"2019","unstructured":"Lomeli\u00a0BK, Galbraith\u00a0H, Schettler\u00a0J, Saviolakis\u00a0GA, El-Amin\u00a0W, Osborn\u00a0B et\u00a0al (2019) Multiple-Ascending-Dose Phase\u00a01 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a\u00a0Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother 64(1):e1395\u201319","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026_CR66","doi-asserted-by":"publisher","first-page":"e0162123","DOI":"10.1128\/aac.01621-23","volume":"68","author":"E Bass\u00e8res","year":"2024","unstructured":"Bass\u00e8res\u00a0E, Eubank\u00a0TA, Begum\u00a0K, Alam\u00a0MJ, Jo\u00a0J, Le\u00a0TM et\u00a0al (2024) Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother 68(3):e162123","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2026_CR67","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/acsinfecdis.2c00445","volume":"8","author":"C Hind","year":"2022","unstructured":"Hind\u00a0C, Clifford\u00a0M, Woolley\u00a0C, Harmer\u00a0J, McGee\u00a0LMC, Tyson-Hirst\u00a0I et\u00a0al (2022) Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP\u20113. ACS Infect Dis 8(12):2552\u20132563","journal-title":"ACS Infect Dis"},{"issue":"23","key":"2026_CR68","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher\u00a0HW, Wilcox\u00a0M, Talbot\u00a0GH, Puttagunta\u00a0S, Das\u00a0AF, Dunne\u00a0MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N\u00a0Engl J Med 370(23):2169\u20132179","journal-title":"N Engl J Med"},{"key":"2026_CR69","unstructured":"Robert Koch-Institut (2025) CC-BY 4.0. https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"key":"2026_CR70","unstructured":"Naghavi M et\u00a0al (2024) Published by Elsevier Ltd., CC-BY 4.0. https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"key":"2026_CR71","unstructured":"Karaiskos I et\u00a0al (2025) CC-BY 4.0. https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"updated-by":[{"DOI":"10.1007\/s00108-026-02100-w","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000}}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02026-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:03:18Z","timestamp":1773475398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02026-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der Originalbeitrag wurde korrigiert: Der urspr\u00fcnglich publizierte Beitrag wies Fehler auf. Diese werden nachfolgend gelistet: In der Zusammenfassung wurde f\u00e4lschlicherweise DTR-GNB genannt. Im Abk\u00fcrzungsverzeichnis wurde urinary tract infection (UTI) f\u00e4lschlicherweise mit \u201ekomplizierte\u201c Harnwegsinfektion \u00fcbersetzt. In Abbildung 3 liegen folgende Fehler vor: Im Tabellenfeld \u201eDTR Pseudomonas aeruginosa - Ceftazidim\/Avibactam\u201c muss die Farbmarkierung gr\u00fcn statt gelb sein. Zu den bereits bekannten hohen Empfindlichkeitsraten (68-89%) kommt eine Leitlinienempfehlung der Infectious Diseases Society of America (IDSA), womit eine Therapie klar empfohlen wird.  Im Tabellenfeld \u201eIndikationen - Meropenem\/Avibactam\u201c muss \u201eIGNB\u201c durch \u201eDTR-GNB\u201c ersetzt werden.  Im Tabellenfeld \u201eIndikationen - Aztreonam\/Avibactam\u201c muss neben \u201ecUTI, cIAI, HAP, VAP, DTR-GNB\u201c auch die wichtige Indikation \u201eBSI\u201c erg\u00e4nzt werden, da auch f\u00fcr BSI (Blutstrominfektionen) eine beh\u00f6rdliche Zulassung vorliegt.  In Abbildung 5 liegt folgender Fehler vor: Im Tabellenfeld \u201eSulbactam\/Durlobactam - OXA (OXA-48, OXA-23)\u201c muss die Farbmarkierung gr\u00fcn statt rot sein, da eine Wirksamkeit gegen\u00fcber OXA-Enzymen gegeben ist.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-026-02100-w","URL":"https:\/\/doi.org\/10.1007\/s00108-026-02100-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0L\u00fcbbert hat Honorare f\u00fcr Vortragst\u00e4tigkeiten und Beraterhonorare von den Firmen Pfizer, Shionogi und Tillotts erhalten. J.\u00a0Tischer, N.\u00a0Dietze, K.\u00a0Marx und H.\u00a0Trawinski geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}